Related Experiment Video

Updated: Jul 17, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

A Phase II Study of Flavopiridol in Patients With Previously Untreated Advanced Soft Tissue Sarcoma

Don G Morris1, Vivien H C Bramwell, Robert Turcotte

  • 1Department of Medicine, Tom Baker Cancer Centre, University of Calgary, Alberta, Canada T2N 4N2.

Sarcoma
|January 26, 2007
PubMed

Insights

Flavopiridol, a cyclin-dependent kinase (CDK) inhibitor, showed no objective responses in soft tissue sarcoma patients. While well-tolerated, it does not support further investigation as a monotherapy.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Flavopiridol is a potent cyclin-dependent kinase (CDK) inhibitor with demonstrated preclinical anti-cancer activity.
  • Soft tissue sarcoma is a group of rare cancers that can be locally advanced or metastatic.

Purpose of the Study:

  • To evaluate the activity and toxicity of flavopiridol in patients with previously untreated metastatic or locally advanced soft tissue sarcoma.
  • To determine the optimal dose and schedule for flavopiridol in this patient population.

Main Methods:

  • A phase II, nonrandomized, nonblinded, multicenter clinical trial was conducted.
  • Eighteen patients with soft tissue sarcoma received flavopiridol at 50 mg/m(2) intravenously over 1 hour daily for 3 days every 3 weeks.

Main Results:

  • No objective responses were observed in the 17 evaluable patients.
  • Forty-seven percent of patients achieved stable disease for a median duration of 4.3 months.
  • Grade 3 toxicities included diarrhea, nausea, gastritis, and fatigue. Flavopiridol was well tolerated, with 94% of patients receiving 90% of the planned dose intensity.

Conclusions:

  • Flavopiridol was well tolerated at the tested dose and schedule in patients with soft tissue sarcoma.
  • The lack of objective responses suggests that flavopiridol as a monotherapy is not effective for this indication at this dose and schedule.
  • Further exploration of flavopiridol as a monotherapy in soft tissue sarcomas is not supported by these findings.

More Related Videos

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver09:02

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Phase II Reactions: Glucuronidation01:24

Phase II Reactions: Glucuronidation

Glucuronidation, a pivotal phase II biotransformation process, involves the coupling of glucuronic acid to a drug or xenobiotic. Given its widespread occurrence and critical role in drug metabolism, it's considered the most crucial phase II reaction. It enhances the water solubility of substances, aiding their expulsion from the body. The driving force behind these reactions is a group of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs facilitate the transfer of a glucuronic acid...